8-K: Aquestive Therapeutics Reports Progress on Anaphylm, AQST-108, and Libervant in Q4 and Full Year 2024 Results

Aquestive Therapeutics announces progress on key pipeline products including Anaphylm NDA filing, AQST-108 Phase 2a trial, and Libervant commercialization, while reporting financial results for Q4 and full year 2024.

Summary

• Aquestive Therapeutics reported its Q4 and full year 2024 financial results and provided a business update.
• The company initiated the NDA filing process with the FDA for Anaphylm (epinephrine) Sublingual Film.
• Anaphylm's pre-commercial activities are underway, with a launch expected in Q1 2026, pending FDA approval.
• Initial pediatric clinical trial results for Anaphylm in subjects 7-17 years of age were in line with expectations.
• The Phase 2a clinical trial for AQST-108 (epinephrine) Topical Gel is on track to begin in Q2 2025.
• Proforma cash and cash equivalents as of December 31, 2024, were approximately $93.0 million, including $21.4 million from an ATM facility in February 2025.
• Total revenues decreased to $11.9 million in Q4 2024 from $13.2 million in Q4 2023, and increased to $57.6 million for the full year 2024 from $50.6 million for the full year 2023.
• The net loss for Q4 2024 was $17.1 million, or ($0.19) per share, compared to a net loss of $8.1 million, or ($0.12) per share, for Q4 2023.
• The net loss for the full year 2024 was $44.1 million, or ($0.51) per share, compared to a net loss of $7.9 million, or ($0.13) per share, for the full year 2023.
• The company expects total revenues of $47 to $56 million and a Non-GAAP adjusted EBITDA loss of $46 to $53 million for 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is making progress on key pipeline products, but financial losses are increasing and there are regulatory and legal challenges.

Positives

• The NDA filing process for Anaphylm has been initiated, moving the product closer to potential market launch.
• Initial pediatric clinical trial results for Anaphylm were in line with expectations.
• The Phase 2a clinical trial for AQST-108 is progressing as planned.
• Libervant is now fully available through national retail distribution, increasing patient access.
• The company has a strong proforma cash position of approximately $93.0 million as of December 31, 2024.
• Salesforce gaining traction with targeted HCPs for Libervant.
• Payor coverage continues to expand for Libervant.

Negatives

• Total revenues decreased in Q4 2024 compared to Q4 2023.
• The net loss increased for both Q4 and full year 2024 compared to the respective periods in 2023.
• The company is appealing a U.S. District Court ruling regarding Libervant's approval for ARS patients aged 2-5 years, creating uncertainty about its market availability for this age group.
• The company anticipates a Non-GAAP adjusted EBITDA loss of $46 to $53 million for 2025.

Risks

• The FDA may require additional clinical studies for Anaphylm's approval.
• The company may not succeed in appealing the U.S. District Court ruling regarding Libervant.
• There is a risk of eroding market share for Suboxone, which accounts for a substantial part of the company's current operating revenue.
• The company faces risks related to intellectual property rights and infringement claims.
• The company's financial outlook for 2025 includes a significant Non-GAAP adjusted EBITDA loss.

Future Outlook

Aquestive expects total revenues of $47 to $56 million and a Non-GAAP adjusted EBITDA loss of $46 to $53 million for the full year 2025.

Management Comments

• Daniel Barber, President and CEO of Aquestive, stated, 'We are thrilled to announce today the start of our Anaphylm application process with the FDA.'
• Daniel Barber also mentioned the advancement of AQST-108 (epinephrine) Topical Gel into Phase 2a clinical trial development.
• Daniel Barber believes that the company is well-positioned to execute on its strategic priorities and key milestones for 2025.

Industry Context

Aquestive is positioning Anaphylm as a non-device alternative to epinephrine autoinjectors like EpiPen and Auvi-Q. AQST-108 targets the alopecia areata market, competing with existing JAK inhibitors but potentially offering a safer topical alternative. Libervant addresses the need for orally administered rescue medication for seizure clusters in young children, competing with device-based products.

Comparison to Industry Standards

• Anaphylm is being developed as an alternative to epinephrine auto-injectors like EpiPen and Auvi-Q, aiming to provide a more convenient, non-device option.
• AQST-108 is targeting the alopecia areata market, where current treatments like JAK inhibitors (e.g., Olumiant from Eli Lilly, Jakafi from Incyte) have limitations due to systemic side effects and black box warnings.
• Libervant competes with products like Valtoco nasal spray (Neurelis) and Diastat rectal gel (Bausch Health) in the acute repetitive seizure (ARS) market, offering an orally administered alternative.

Legal Proceedings

• The company is appealing the U.S. District Court for the District of Columbia ruling that the FDA erred in approving Libervant for ARS patients between the ages of two and five years.

Stakeholder Impact

• Shareholders: The increasing net losses and regulatory challenges could negatively impact shareholder value.
• Patients: The potential approval and launch of Anaphylm and AQST-108 could provide new treatment options for severe allergic reactions and alopecia areata, respectively.
• Employees: The company's progress on key pipeline products and commercialization efforts could create job opportunities and growth within the company.

Next Steps

• Complete the Anaphylm NDA submission.
• Prepare for a potential Advisory Committee meeting with the FDA regarding Anaphylm.
• Initiate the Phase 2a clinical trial for AQST-108 in Q2 2025.
• Continue commercialization efforts for Libervant.
• Appeal the U.S. District Court ruling regarding Libervant's approval for ARS patients aged 2-5 years.

Key Dates